IQVIA Market Access Launch Pad is a dynamic and comprehensive suite of tools designed to support pharmaceutical companies in their product launch readiness.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.